Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.
Metrics to compare | RUBI | Peers Peers - average of corresponding metrics from companies closely matching RUBI: ACCENTMIC, GLAND, NATCOPHARM, 539730, ALKEM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRUBIPeersSector |
|---|---|---|---|---|
P/E Ratio | 75.8x | 28.6x | −0.6x | |
PEG Ratio | 1.62 | 0.89 | 0.00 | |
Price/Book | - | 3.7x | 2.6x | |
Price / LTM Sales | 7.9x | 3.0x | 3.4x | |
Upside (Analyst Target) | - | 12.4% | 39.1% | |
Fair Value Upside | Unlock | 6.1% | 5.4% | Unlock |